Stoke Therapeutics, Inc.
Stoke Therapeutics (Nasdaq: STOK) is a clinical-stage biotechnology company developing RNA-based medicines to address the underlying causes of severe genetic diseases. Its proprietary TANGO platform uses antisense oligonucleotides to alter RNA splicing and increase production of functional proteins from healthy gene… From the company’s description.
Over the twelve months to Sep 30, 2026, Stoke Therapeutics, Inc. reported revenue of $28.21M, down 86.3% from a year earlier, and a net loss of $243.20M. Its operating margin was −913.2%, and operations used $210.31M in cash. In fiscal 2025, it reported revenue of $184.42M, up 404.5% from fiscal 2024, and a net loss of $6.88M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Stoke Therapeutics, Inc. does
In the company’s own words
Stoke Therapeutics (Nasdaq: STOK) is a clinical-stage biotechnology company developing RNA-based medicines to address the underlying causes of severe genetic diseases. Its proprietary TANGO platform uses antisense oligonucleotides to alter RNA splicing and increase production of functional proteins from healthy gene copies. The lead candidate, zorevunersen, is in Phase 3 development for Dravet syndrome, a genetic epilepsy, while STK-002 is being evaluated in a Phase 1 study for autosomal dominant optic atrophy. The company is also advancing preclinical programs, with a focus on diseases of the central nervous system and eye. Stoke collaborates with Biogen on zorevunersen development and commercialization outside the United States, Canada and Mexico, and with Acadia Pharmaceuticals on a SYNGAP1 program. It reported $[amount] in revenue for fiscal 2025. Its website is [URL].
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BEDFORD, MA
- Fiscal year end
- December
- CIK
- 1623526
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Stoke Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Stoke Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Stoke Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Stoke Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Stoke Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”